Rafferty Asset Management LLC Purchases 394,022 Shares of Recursion Pharmaceuticals, Inc. $RXRX

Rafferty Asset Management LLC boosted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 110.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 750,191 shares of the company’s stock after buying an additional 394,022 shares during the quarter. Rafferty Asset Management LLC’s holdings in Recursion Pharmaceuticals were worth $3,661,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Norges Bank purchased a new position in Recursion Pharmaceuticals in the 2nd quarter worth approximately $16,040,000. Bank Pictet & Cie Europe AG bought a new position in shares of Recursion Pharmaceuticals in the third quarter worth approximately $7,954,000. Vanguard Group Inc. increased its stake in shares of Recursion Pharmaceuticals by 10.3% in the third quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock worth $194,127,000 after buying an additional 3,708,975 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in Recursion Pharmaceuticals by 94.8% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 1,774,995 shares of the company’s stock valued at $8,662,000 after buying an additional 863,910 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in Recursion Pharmaceuticals during the 2nd quarter valued at $892,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Najat Khan sold 124,403 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $4.41, for a total value of $548,617.23. Following the sale, the insider directly owned 611,135 shares of the company’s stock, valued at $2,695,105.35. The trade was a 16.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Ben R. Taylor sold 21,383 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $4.18, for a total value of $89,380.94. Following the completion of the sale, the chief financial officer owned 761,550 shares in the company, valued at $3,183,279. The trade was a 2.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 599,212 shares of company stock worth $2,562,550. 8.43% of the stock is owned by corporate insiders.

Analyst Ratings Changes

RXRX has been the topic of a number of analyst reports. Bank of America decreased their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $10.00 to $11.00 in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. UBS Group set a $11.00 price objective on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Finally, Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $3.54 on Wednesday. The company has a 50-day simple moving average of $4.15 and a two-hundred day simple moving average of $4.66. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.50 and a quick ratio of 5.50. The firm has a market capitalization of $1.84 billion, a PE ratio of -2.39 and a beta of 0.97. Recursion Pharmaceuticals, Inc. has a one year low of $2.98 and a one year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, February 25th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The firm had revenue of $35.54 million for the quarter, compared to the consensus estimate of $24.56 million. During the same quarter in the prior year, the business earned ($0.53) EPS. The business’s revenue for the quarter was up 671.7% on a year-over-year basis. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.